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Abstract
Purpose: We analyzed our long-term experience with fractionated stereotactic radiotherapy (FSRT) in patients with
meningioma of the optic nerve sheath (ONSM).
Patients and Methods: Between January 1991 and January 2010, 40 patients with ONSM were treated using FSRT.
Of these, 19 patients received radiotherapy as primary treatment, and 21 patients were treated after surgical
resection. The median target volume was 9.2 ml, median total dose was 54 Gy in median single fractions of 1,8 Gy.
Results: Local progression-free survival was 100%. Median survival after FSRT was 60 months (range 4-228 months).
In all patients overall toleration of FSRT was very good. Acute toxicity was mild. Prior to RT, 29 patients complained
about any kind of visual impairment including visual field deficits, diplopia or amaurosis. Prior surgical resection
was identified as a negative prognostic factor for visual outcome, whereas patients with larger tumor volumes
demonstrated a higher number of patients with improvement of pre-existing visual deficits.
Conclusion: Long-term outcome after FSRT for ONSM shows improved vision in patients not treated surgically
prior to RT; moreover, the best improvement of visual deficits are observed in patients with larger target volumes.
The absence of tumor recurrences supports that FSRT is a strong alternative to surgical resection especially in small
tumors without extensive compression of normal tissue structures
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Introduction
Treatment of primary optic nerve sheath meningiomas
(ONSM) remains a challenge in the interdisciplinary
team of surgeons, opthalmologists and radiation oncolo-
gists. They are located directly adjacent to the optic
nerve which is sensitive to any treatment damage,
including radiation or surgical procedures. They arise
from meningothelial cap cells of arachniod villi which
surround the optical nerve within the orbit or within
the intracanalicular part of the optic nerve.
In general, menigiomas are slow growing tumors with
an annual incidence of 6 per 100,000; most patients
remain without any clinical symptoms over very long
periods of time. ONSM are a rare subtype accounting
for 2% of all meningiomas, but they represent the sec-
ond most frequent optic nerve tumors [1-3]. Initially
believed to be extremely rare, ONSM diagnosis
increased steadily with continuous optimization of neu-
roimaging in the CT and MRI era. Benign meningiomas
mostly occur in middle-aged or elderly adults, and
women are affected twice as often than men. About 30-
60% of all intraorbital meningeomas are primary ONSM
[3-6]. The vast majority of ONSM are unilateral and
become noticeable through painless loss of visual acuity
[1,7-12].
For treatment of ONSM, surgical resection can be of
choice for certain cases, especially for large tumors lead-
ing to intraorbital pressure and compression; for asymp-
tomatic patients, however, also a wait-and-see strategy
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might be followed, and patients with remaining useful
vision and no tumor progression have been observed in
the past [13].
One main risk associated with surgery is the often
inevitable dissection of the vascular supply of the nerve,
which leads to severe visual impairment in about 95% of
the patients [3]. There have been only a few series with
improved vision after surgical treatment [14,15].
Modern photon radiation techniques such Fractio-
nated Stereotactic Radiotherapy (FSRT) have been estab-
lished in clinical routine enabling the delivery of highly
conformal doses with steep dose gradients to normal tis-
sue. With these techniques, precise treatment of malig-
nant and non-malignant target lesions in close vicinity
to organs at risk is possible. For ONSM, several groups
have reported excellent clinical outcome with low rates
of side effects, however, in small series with only short
or mid-term follow-up [4,9-12,16]. In spite of the con-
vincing results in ONSM it is still discussed controver-
sially whether benign ONSM should be irradiated
directly after diagnosis, postoperatively after subtotal
neurosurgical resection or at the time of clinical or mor-
phological progression during follow-up.
In the present analysis we report our long-term results
a large patient group with ONSM treated with FSRT.
Special focus is set on the evaluation of prognostic fac-
tors as well as long-term preservation of quality of life.
Patients and Methods
Forty consecutive patients with ONSM treated with
FSRT between January 1991 and January 2010 at the
Department of Radiation Oncology and the Germany
Cancer Research Center (dkfz) in Heidelberg, Germany,
were included into this analysis.
Patients were followed prospectively. Additionally, we
sent out a detailed questionnaire to all patients asking
about recent neurological status including cranial nerve
deficits, side effects after treatment during follow-up,
additional treatments for ONSM, quality of life prior to
and after FSRT as well as any improvement in pre-exist-
ing sequelae. This questionnaire was returned in 32 out
of the 40 patients (80%).
The median age at the time of radiotherapy was 44 years
(range 17-83 years). The tumor manifestation was on the
right eye in 16 patients and on the left eye in 23 patients.
In one patient both eyes were affected. The female to male
ratio was about 2:1 (26 females and 14 males). Patients’
characteristics are summarized in table 1.
For 19 patients treatment was recommended as pri-
mary treatment, and 21 were treated after surgical resec-
tion. Of these, 12 were treated for tumor progression of
progressive clinical symptoms during follow up. In 9
patients, RT had been conducted immediately post-
operatively. From those who underwent previous surgery
all had been initially diagnosed with benign WHO
Grade I meningiomas.
The median time between surgical resection and
radiation therapy was 43 months.
The median period between surgery and RT was 3
months (range 1-7 months) for those treated immedi-
ately postoperatively, and a median of 56 months (range
2-132 months) for those treated for progression of
ONSM after surgical resection.
All patients were treated with FSRT. For treatment
planning, patients were fixed with a custom-made
Scotch cast® mask; this mask allows an overall position-
ing accuracy of 1-2 mm. With the mask fixed to the
stereotactic base frame, contrast-enhanced CT and MRI
scans were performed for treatment planning. For
patients without prior histological confirmation, an addi-
tional PET using 68Ga-DOTATOC was performed as
reported previously [17,18] to support the clinical as
well as MR-imaging based diagnosis of meningioma.
Typical examinations for treatment planning are shown
in Figure 1.
We defined the macroscopic lesion visible on con-
trast-enhanced MRI as the gross tumor volume (GTV),
adding 1-2 mm safety margin for the planning target
volume (PTV). The median PTV was 9.2 ml. Radiother-
apy planning for FSRT was performed using the Voxel-
plan® software developed at the German Cancer
Research Center (dkfz) or the STP software (Stryker,
Leibinger). Three to four non-coplanar isocentric fields
Table 1 Patients’ characteristics of 40 patients with











primary radiotherapy 19 (48)
directly post-surgery 9 (22)
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irregularly shaped with a micro-multileaf collimator
were used. The median dose to the PTV was 54 Gy
(range 25-66 Gy) in fractions of 1.8 - 5 Gy. None of the
patients received concomitant chemotherapy.
All photon plans were delivered using a 6 MeV linear
accelerator (Siemens, Erlangen, Germany)
The median follow-up time was 60 months (range
from 4 - 228 months). All patients were seen on regular
intervals for clinical follow-up, as well as for MR-ima-
ging. The first follow-up examination was scheduled 6
weeks after completion of RT, then in three months
intervals for the first year. Thereafter, yearly follow-up
visits were scheduled. Clinical examination included
thorough neurological assessment and visual assessment
through fomal opthalmologis assessment by the opthal-
mologist. Other examinations, such as endocrinological
evaluation, were scheduled depending on the dose distri-
bution of the treatment plan as well as on a clinical
basis. Progression-free survival was determined based on
the RECIST criteria evaluating two orthogonal diameters
of the lesion. Tumor progression was determined by an
increase in tumor size of more than 35% (product of the
two orthogonal diameters) or any increase in tumor size
on subsequent imaging examinations. Overall survival
was calculated from the date of the first diagnosis to the
last follow-up or death (by any cause). Survival after
irradiation was calculated from initiation of irradiation.
Progression-free survival was calculated from the first
day of irradiation until tumor progression or death (also
any cause), whichever occurred first, using the Kaplan-
Meier method. Influence on prognostic factors on out-
come was assessed using the univariate Cox propor-
tional regression model. Statistical analyses were
performed with the software program Statistica 6.1
(StatSoft, Hamburg, Germany).
Results
Local control and Survival after FSRT
During follow-up, no patient developed imaging-defined
progression of the ONSM after FSRT. Therefore, local
progression-free survival was 100% at a median follow-
up time of 60 months (range 4-228 months).
Survival was 93% at 5 years after FSRT, all deaths
were non-related to the ONSM.
Overall Toxicity
In all patients overall toleration of FSRT was very good.
Acute toxicity was mild. Most patients experienced local
alopecia restricted to small regions. Fatigue was a com-
mon complaint of one fifth of the 40 patients. Two
patients presented with xerophthalmia, and on patient
developed acute conjunctivitis during treatment. During
short-term follow up, one patient complained of new
headaches, and three of recurrent hyperlacrimation of
the irradiated eye, one with change of taste perception.
None of the patients developed dysfunctions of the
pituitary gland, neuropathy, retinopathy or brain necro-
sis. One patient complained of scotoma and visual disor-
der during FSRT, which receded completely after
application of steroids. However, after termination of
steroid medication, symptoms returned; the ONSM was
removed surgically 6 months after completion of FSRT.
In this patient, a dose of 52.2 Gy had been applied, in
single doses of 1.8 Gy.
Visual outcome
Prior to RT, 29 patients complained about any kind of
visual impairment including visual field deficits, diplopia
or amaurosis (see table 1). Of these patients, 15 had
been treated with prior surgical resection (52%), and 14
patients were treated with FSRT as primary treatment
without prior surgical intervention (48%). Therefore, of
all patients treated with prior surgical resection, 15 out
of 21 (71%) presented with pre-existing visual deficits, of
which 4 presented with complete amaurosis. In the
group without surgical intervention, 14 out of 19 (74%)
complained of visual deficits, with 2 patients presenting
with complete amaurosis.
During follow-up after FSRT, vision improved in 12
out of 27 patients with pre-existing impairments (44%).
In the surgery group, 3 patients showed improvement
(20%), whereas in the RT-only group 9 patients showed
symptom improvement during follow up (75%; Figure
2). This difference was statistically significant at p <
0.005.
Only one patient developed visual impairment after
FSRT with respect to visual field deficits, and two
patients complained of slight decrease of vision acuity.
No severe side effects could be observed, and none of
the patients developed new visual deficits.
With respect to treatment volume during FSRT,
patients with larger target volumes showed significantly
more improvement of visual function than patients with
smaller volumes (p < 0.005; Figure 3).
Figure 1 Treatment-planning examinations for a patient with
right-sided ONSM for primary FSRT. CT (A), MRI (B) and 86-Ga-
DOTATOC-Pet (C) were used for treatment planning after image-
fusion, a dose of 54 Gy was prescribed in 1.8 Gy single doses.
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Discussion
The present manuscript supports previous reports and
reinforces that high precision radiotherapy offers a highly
effective treatment modality for patients with ONSM.
Local control rates are excellent, and the rates of treat-
ment-related side effects are minimal. The best response
with respect to improvement of vision can be observed in
patients treated with FSRT as primary definitive treat-
ments, whereas surgically pre-treated patients demon-
strate lower rates of improving symptoms. Additionally,
patients with larger treatment volumes are more likely to
show improvement of pre-exisiting clinical symptoms.
Several groups have reported their clinical results of
precision radiotherapy for the treatment of ONSM
[6,8-10,16,19-21]. All authors agree that local control
can be achieved safely with very low recurrence rates as
well as low rates of treatment-related side effects. How-
ever, since most patients with ONSM are younger
patients with long-term survival after treatment, not
only prevention of side effects if of high importance, but
also improvement of pre-existing clinical symptoms.
A number of studies have shown that FSRT in addi-
tion to preservation of visual function, even improve-
ment in pre-existing clinical symptoms, such as visual
acuity, can be achieved [4,8,9,11,16,21,22]. At MGH in
Boston, 25 patients with ONSM treated with highly con-
formal radiotherapy using protons or photons reported
95% improvement or stable vision during follow-up [22].
Turbin and colleagues published retrospective data on
64 patients with ONSM treated with observation, sur-
gery, surgery combined with radiotherapy as well as
radiation alone: Of all patients, the group treated with
radiation alone showed the best results with respect to
vision preservation, although about one third of the
patients developed treatment-related side effects such as
retinopathy or temporal lobe reactions [7]. However, no
direct link to the implemented radiation techniques was
reported, and due to the multicentric nature of the
study it is most likely that not all centers treated with
the most advanced methods available at that time.
Therefore, direct comparison with modern stereotactic
methods or proton radiotherapy might not be possible.
With reports focussing on modern stereotactic techni-
ques, improvement in visual function was reported to be
between 42% and 85% [8,9,11,23,24].
Since in the past, neurosurgical resection was often
considered the standard approach for ONSM, individual
weighing of the risk-benefit-ratio in patients with
ONSM is required, when deciding for a specific therapy.
Until now, no direct randomized trials compare surgery
with radiation. However, some authors have addressed
side effects after both treatments: Andrewas and collea-
gues could show in 30 patients with ONSM that, com-
pared to historical controls, patients treated with RT
showed no evidence of tumor progression, and 150%
higher probability of visual improvement during follow-
up [9]. Turbin and colleagues evaluated 64 patients with
ONSM, comparing observation, surgery, surgery and
radiation as well as radiation alone. The results demon-
strated that patients receiving radiation alone showed
the highest rate of vision preservation [7]. In all studies,
radiation doses between 50 and 55 Gy were applied. In
our group a median dose fo 54 Gy in single fraction of
median 1.8 Gy were applied, which is well in line with
the reported doses in the literature.
Our data presented in the present manuscript also
show that stable or improved vision can be achieved in
the majority of patients with ONSM treated with FSRT.
Figure 2 Patients with visual impairment prior to FSRT and
development of symptoms during follow up. Patients previously
treated with surgical interventions showed higher numbers of
symptoms prior to RT. During follow-up, surgery-naive patients
demonstrated significantly higher rates of improvements.
Figure 3 Correlation of PTV-size and visual outcome. Patients
with smaller treatment volumes were more likely to present with
stable disease, whereas patients with larger volumes showed a
higher rate of visual improvement during follow-up.
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From the present data analyzed, we must emphasize that
patients treated with radiation therapy as primary defini-
tive treatment demonstrate the best improvement in
visual deficits: Patients previously treated with surgical
resection, although not showing a difference in local
tumor control or toxicity, show lower rates of improve-
ment with respect to visual deficits. This is most likely
due to the differences in damage to the optic structures
leading to visual impairment. Patients after surgery
appear to present with more severe and irreversible
symptoms, whereas patients in the radiation-only group
suffer from symptoms caused by compression of the
ONSM of normal tissue structures. In the orbial region
very small changes in normal tissue and tumor geometry
can have a major impact on organ and nerve function
due to the very narrow architecture. Thus, imaging-
defined stable tumors potentially associated with a slight
tumor regression (not visible on imaging) may lead to a
major decompression (due to the tight anatomical struc-
tures), improvement in visual impairment caused by
tumor compression or more likely after FSRT.
This can be supported by the effect of tumor size on
visual outcome: Additionally, our study revealed that
patients with larger tumor volumes and thus larger
treatment volumes for radiation demonstrate higher
rates of improvement with respect to visual function,
most likely since these symptoms originate from tumor
mass effect declining after FSRT. However, in total,
results are based on a limited number of patients, and
no formal randomized clincial trial was performed to
compare different treatment modalities.
Conclusion
In conclusion, FSRT can achieve long-term control of
ONSM without high-rates of treatment related side
effects. Patients treated with prior surgical resection
show reduced improvement of visual function, support-
ing the idea that surgery might be better reserved for
large tumors with major compression and subsequent
clinical symptoms, such as exophthalmia. For tumors
with compression and acute symptomas surgery must
be evaluated. Doses of 50-55 Gy in normofractionated
regimens show safety even after long-term follow-up.
Novel concepts evaluating hypofractionated regimens
are currently under investigation, but should be applied
cauteously within clinical trials to safely assess toxicity.
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